GRACEcast
ASCO Lung Cancer Highlights, Part 10: Strategies After Resistance to Crizotinib in ALK-Positive Advanced NSCLC (audio)
- Author: Podcast
- Narrator: Podcast
- Publisher: Podcast
- Duration: 0:05:45
- More information
Informações:
Synopsis
Dr. Edward Garon, David Geffen School of Medicine at UCLA, describes the exciting developments with LDK-378 and potentially other second generation ALK inhibitors for crizotinib-resistant ALK-positive advanced NSCLC.
